VAXCYTE, INC. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
VAXCYTE, INC. (PCVX) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax of $8.69 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-05.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax · last filed 2024-11-05
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2024-09-30 was $8.69M, a 3662.77% increase year-over-year.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2024-06-30 was -$445.00K.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2024-03-31 was -$2.00M, a 589.95% decline year-over-year.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2023-09-30 was $231.00K, a 6.48% decline year-over-year.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2023 was $538.00K.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2022 was -$120.00K.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2021 was -$241.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 12 month |
|---|---|---|---|---|
| 2024-09-30 | $8.69M 10-Q · filed 2024-11-05 | $8.25M derived: sum of 2 quarters · filed 2024-11-05 | $6.25M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2024-06-30 | -$445.00K 10-Q · filed 2024-11-05 | -$2.44M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2024-03-31 | -$2.00M 10-Q · filed 2024-11-05 | |||
| 2023-12-31 | $538.00K 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $231.00K 10-Q · filed 2024-11-05 | -$2.34M derived: sum of 2 quarters · filed 2024-11-05 | -$1.93M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | -$2.57M 10-Q · filed 2024-11-05 | -$2.16M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $408.00K 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | -$120.00K 10-K · filed 2024-02-27 | |||
| 2022-09-30 | $247.00K 10-Q · filed 2023-11-06 | $176.00K derived: sum of 2 quarters · filed 2023-11-06 | -$416.00K derived: sum of 3 quarters · filed 2023-11-06 | |
| 2022-06-30 | -$71.00K 10-Q · filed 2023-11-06 | -$663.00K derived: sum of 2 quarters · filed 2023-11-06 | ||
| 2022-03-31 | -$592.00K 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | -$241.00K 10-K · filed 2024-02-27 | |||
| 2021-09-30 | -$4.00K 10-Q · filed 2022-11-07 | $35.00K derived: sum of 2 quarters · filed 2022-11-07 | -$12.00K derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $39.00K 10-Q · filed 2022-11-07 | -$8.00K derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | -$47.00K 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |